Progenics Pharmaceuticals Inc. and Wyeth Llc | Date: 2015-08-07
The present invention provides a new forms of (R)N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
Progenics Pharmaceuticals. Inc. | Date: 2013-06-06
This invention relates to synthesis of (R),(R)-2,2-bis-MNTX, as shown in Formula (I), and related methods and products.
Progenics Pharmaceuticals Inc. | Date: 2015-06-22
This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.
Wyeth Llc and Progenics Pharmaceuticals Inc. | Date: 2013-09-04
Olson W.C.,Progenics Pharmaceuticals Inc. |
Israel R.J.,Progenics Pharmaceuticals Inc.
Frontiers in Bioscience - Landmark | Year: 2014
Prostate-specific membrane antigen (PSMA) is an integral, non-shed membrane glycoprotein that is a well-characterized and clinically validated marker of prostate cancer. The expression profile and other biological properties of PSMA make it an attractive target for antibody-drug conjugate (ADC) therapy of prostate cancer, as well as a broad range of other tumors in which PSMA is abundantly expressed within the tumor neovasculature. PSMA-targeted ADCs have been developed using auristatin and maytansinoid drugs, and each ADC has undergone extensive preclinical testing and has completed phase 1 testing in men with advanced prostate cancer. The preclinical and clinical findings have largely substantiated the promise of PSMA as an ADC target. This report summarizes the completed studies, current status, and potential future directions for ADCs that target PSMA.